BSX Stock Analysis — Boston Scientific
Sector: Healthcare
AI Verdict
BSX trades at 14.1x next year's earnings with 34.0% EPS growth expected — that's cheap for a healthcare name if its regulatory and hospital relationships remain sticky.
Competitive Moat
Boston Scientific specializes in minimally invasive medical devices for cardiology, electrophysiology, and endoscopy, with deep integration into hospital procurement and physician training. Its defensibility comes from regulatory approvals, clinical data, and embedded relationships with health systems that create high switching costs.
Summary
Boston Scientific is trading at a steep discount to its historical growth rate after a year of sharp underperformance.
Where It Stands
With a 1-year return of -55.87%, an RSI of 40.9 signaling cooling sentiment, and a forward P/E of 14.1x versus the healthcare sector median of 22x, BSX is priced well below peers despite double-digit growth expectations.
Key Metrics
- RSI: 40.9 — Neutral
- Trailing P/E: 18.9x
- Forward P/E: 14.1x
- PEG Ratio: 0.60
- Earnings Growth: +0.3%
- Market Cap: $67.6B
- 1-Year Return: -55.87%
Analyst Consensus
30 Buy · 8 Hold · 0 Sell (38 analysts)
Bull Case
Analysts expect 34.0% EPS growth next year, making the 14.1x forward P/E cheap for the growth on offer if the company's entrenched hospital relationships hold.
Bear Case
If the P/E reverts to the 12x energy sector median instead of healthcare's 22x, shares could see another 15% downside from here.
Catalyst to Watch
Watch for FDA approvals or clinical trial results that could reinforce or undermine the company's hospital integration moat.